CAD & ACS & CHF Flashcards
(36 cards)
Risk Factors of CAD
NM: age, gender, ethnicity, family HX, genetic
M: hyperlipidemia, HTN, Tobacco use, physical inactivity, obesity
CAD: contributing factors
Elevated homocysteine levels
- Breakdown of AA
DM
Metabolic syndrome
- Increased waist circ
- HTN
- abnormal serum lipids
- elevated fasting glucose
Stress
Substance abuse
Angina
Clinical manifestation of REVERSIBLE myocardial ischemia
MI (Myocardial infarction)
IRREVERSIBLE necrosis caused by abrupt decrease or cessation of coronary blood flow
Assessment of chest pain
location
duration
quality
radiation
precipating factor
medication relief
EKG changes
Gender differences in cardiac disorders
Prodromal symtoms
women:
-fatigue, SOB, indigestion, anxiety
Core measures: ACS
ST elevation or new BBB
- thrombolytic ( clot busting drugs) within 30 mins of hospital arrival
- PCI within 45-90 mins of hospital arrival
ASA within 24-hours of hospital arrival
Admission to CCU within 30 mins after initial EKG (STEMI)
smoking cessation education
Discharge RX
- B-Blockers
- ACE1/ARB for EF less than 40%
- ASA
Cardiac Phase I activity standards
Medical management of UA or NSTEMI w/ negative markers & on-going angina
-ASA
-heparin (IV or LMWH)
- glycoprotein inhibitor (Integrillin)
- Angio w/ PCI when stable
Medical management of STEMI or NSTEMI w/ positive markers
reperfusion therapy
- emergent PCI
- Fibrinolytic therapy
- Surgical revascularization
Creatine Kinase (total CK)
used to support Dx of myocardial injury, neurologic or skeletal muscle disease
levels rise 6-hours after injury, peak 18-hours, normalize in 2-3 days
Isoenzymes
CK-MM 100% (all circulating CK, muscle injury)
CK-MB 0% (specific for cardiac cells)
- usually do NOT rise with angina, PE, CHF
- Rise 3-6 hours, peak 12- 24 hours, normalize 12- 48 hours
- quantify degree of MI & timing of onset
Shock, malignant hyperthermia, myopathy, myocarditis
- rise in unstable angina signifies increased risk of MI
Determine appropriateness of thrombylotic therapy
Troponins
Specific indicator of cardiac injury
determines if chest pain is caused by cardiac ischemia
helps predict risk of future events
- elevate sooner & remain elevated longer ( 7-14 days)
Diagnosis MI
Troponin T: less than .2 ng/ml
Troponin I: less than .3 ng/ml
Medical management of CAD/Angina
Restoration of blood supply
Precutaneous coronary intervention
Nursing management of CAD
modifiable risk factor reduction
Sex activity CAD
7-10 days without complications
Complications of AMI/ACS
Dysrhythmias
cariogenic shock
papillary muscle dysfunction or rupture
pericarditis (pericardial friction rub)
- Dressler syndrome= pericarditis + effusion + fever
Venticular aneurysm
- thrombi= lead to stroke
Ventricular rupture
Pathophysiology of HF
Ventricular dilation
Increased SNS stimulation
Stimulation RAAS
De-compensated HF
- Pulmonary edema
Left-ventricular Failure
Back-up to LA into pulmonary veins leads to increased pulmonary pressure leads to pulmonary congestion, pulmonary edema
Right-ventricular failure
back up to RA & venous circulation leads to systemic congestion leads to Jugular vein distention, hepatomegaly, splenomegaly, GI vascular congestion, Peripheral edema
Complication of HF
Pleural effusion
Dysrhythmias
LV thrombus
Hepatomegaly
Renal failure
Diagnostics of HF
ANP/BNP
Echocardigram
Doppler flow
Chest X-Ray
EKG
ABG analysis
Liver enzymes
BUN/Cr
Atrial natriuretic peptide (ANP)
22-77pg/ml
Synthesized in cardiac muscle
Brain natriuretic peptide (BNP)
100 less pg/mL
main source cardiac ventricle
d/t atrial / ventricular stretch causing
- vaso-relaxation
- inhibition of adrenal aldosterone secretion
- inhibition of RAAS
Implications of HTN, CHF, Atherosclerosis
Ventricular peptide
Management of HF
Improve ventricular (pump) performance
Reduce workload
Reduce fluid retention
Reduce stress & risk of injury
Medications
- diuretics
- vasodilators
- Morphine
- Positive Inotropes
- digoxin (LV function)
- loading dose; not for initial treatment
Surgical:
- transplantation